Fidia, recombinant Hyaluronidase: the future driving force of Pharmacology is recombinant Hyaluronidase from Italy: more efficiency and safety. The CEO of Fidia, Giorgio Foresti: Will foster a valuable asset of Italian research for the industry and the therapy, the investment and the improvement of the quality of life of patients. Abano Terme (Padua), 21 October 2013 Fidia Farmaceutici is a leading company in the production and marketing of innovative medicines on the basis of hyaluronic acid and its derivatives. The researchers succeeded in Noto (Sicily), to identify a strain of the Microbe, and to isolate a Hyaluronidase with increased enzyme activity. Because this recombinant enzyme comes from non-pathogenic micro-organisms, it is very safe. This efficient but in all its possible applications at the same time secure molecule focus coming 22 to 24 October in Frankfurt at CPhI 2013 presented, the most important international meeting for all pharmaceutical aspects of the production of Active substances and chemicals up to the supply of vessels and compositions.
Fidia takes part in the event at booth 30 B 18. The development of Hyaluronidase by Fidia is an excellent example of a virtuous spiral by excellent research in motion”explained Giorgio Foresti, CEO of Fidia Farmaceutici starting from a theoretical intuition we were made in Italy able, a valuable asset for our company and for the trademark? to generate. Our new Hyaluronidase is a proprietary product, we have applied for the patent. It offers more efficiency and unprecedented safety first and foremost. Just as important the future further developments of this protein will be, that will show its outstanding properties in combination with other active ingredients and promises so a successful collaboration with major pharmaceutical companies. The message is clear: A great asset of Italian research for the industry and the therapy, the incentives for investing in the improvement of the Quality of life of patients will create.